Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ITV Extension Study

This study has been completed.
The University of New South Wales
Virax Pty. Ltd,
Information provided by:
Kirby Institute Identifier:
First received: June 1, 2006
Last updated: February 26, 2007
Last verified: June 2006
The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine candidate study is to provide proof of concept for a HIV antigen delivery system in terms of safety, virological effects and selected immune responses in HIV infected individuals after cessation of antiretroviral combination therapy (ART).

Condition Intervention Phase
Biological: recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens
Biological: HIV gag-pol antigens and interferon-gamma (IFN-y)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)

Resource links provided by NLM:

Further study details as provided by Kirby Institute:

Primary Outcome Measures:
  • Time weighted area under the curve change from plasma HIV-RNA VL at baseline (day 0) until reintroduction of antiretroviral therapy

Secondary Outcome Measures:
  • Log plasma HIV-RNA load after cessation of combination ART (post-vaccination viral load (VL) set-point)
  • Kinetics and rate of VL recrudescence and median time to re-initiation of ART
  • CD8+ T-cell responses to HIV antigens assessed through:
  • Enzyme linked immunospot (ELISPOT) assay of IFN-y secreting cells
  • Intracellular Cytokine Cytometry (ICC) for IFN-y and CD69
  • Human Leucocyte Antigen (HLA) class I/ I matched tetramer analyses for HIV epitope specific CD8+/CD4+ T –cells
  • CD4+/CD8+ T-cell count changes

Estimated Enrollment: 35
Study Start Date: September 2002
Estimated Study Completion Date: September 2003
Detailed Description:
A multi-centre, double-blind, placebo-controlled, 20-week parallel group extension study to the VIR-NCHR-01 protocol (ITV study). The purpose of the extension study is to assess the safety and virological effects of a therapeutic HIV vaccine strategy in HIV-1 infected adults currently enrolled in the ITV study after cessation of antiretroviral therapy. Two active candidate vaccines will be studied in this trial: The active treatment arms will receive recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens or HIV gag-pol antigens and interferon-gamma (IFN-y) in diluent. Vaccines will be delivered by intramuscular injection.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infected individuals eligible and still fulfilling the criteria for the VIR-NCHR-01 protocol (ITV study)
  • Received all 3 immunisations
  • Remained in follow-up for at least 52 weeks
  • Continued to take combination antiretroviral therapy with no evidence of treatment failure at the time entering the roll-over phase
  • Written informed consent obtained

Criteria for Withdrawal of Study Participants

  • Incidental or progression of disease which, in the opinion of the principal investigator, should preclude further study participation
  • If the study participant required cytotoxic or immunosuppressive chemo- or radiation therapy
  • If the study participant required any medications that when combined with the study vaccination, would in the opinion of the principal investigator, jeopardise the validity of the individual’s continued participation
  • Administration of prohibited alternative therapy
  • Study participant non-compliance
  • All study participants are required to adhere to the protocol evaluation schedule. Failure to adhere with this schedule without having first provided justification may result in the participant being withdrawn from the study
  • At the request of the study participant or principal investigator without prejudice to future health care
  • In the opinion of the investigator, if it is not in the patient’s best interests to continue the study
  • At the request of the National Centre in HIV Epidemiology and Clinical Research (NCHECR) with reasonable cause
  • At the advice of the Data Safety Monitoring Board (DSMB)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00332930

Australia, New South Wales
407 Doctors
Sydney, New South Wales, Australia, 2010
Ground Zero Medical Practice
Sydney, New South Wales, Australia, 2010
Holdsworth House Medical Practice
Sydney, New South Wales, Australia, 2010
St Vincents Hospital
Sydney, New South Wales, Australia, 2010
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Carlton Clinic
Melbourne, Victoria, Australia, 3053
Sponsors and Collaborators
Kirby Institute
The University of New South Wales
Virax Pty. Ltd,
Principal Investigator: David A Cooper, AO DSc MD FRACP FRCPA FRCP National Centre in HIV Epidemiology and Clinical Research.
  More Information Identifier: NCT00332930     History of Changes
Other Study ID Numbers: VIR-NCHR-02
Study First Received: June 1, 2006
Last Updated: February 26, 2007

Keywords provided by Kirby Institute:
Therapeutic vaccine

Additional relevant MeSH terms:
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on May 25, 2017